Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* newly diagnosed or diagnosis of relapsing (relapsed \<= 6 weeks to baseline) mild to moderate ulcerative colitis~* women not of childbearing potential or WOCP who agreed to use an effective contraceptive method~Exclusion Criteria:~* severe ulcerative colitis or relapsed for \> 6 weeks prior to baseline~* subjects who had relapsed on maintenance therapy with doses of mesalazine \> 2.0 g/day~* subjects with Crohn's disease, proctitis, bleeding disorders or active peptic ulcer disease~* subjects with asthma if they were known to be mesalazine-sensitive~* subjects who were at immediate or significant risk of toxic megacolon~* subjects who had previous resective colonic surgery~* subjects who had moderate or severe renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).